PT-141
Bremelanotide
A Central Pathway Approach to Sexual Health and Desire
1,000 + Patients Served
24 /7 Telehealth Access
15 + Treatments Available
98 % Patient Satisfaction
Overview
PT-141 (bremelanotide) is a melanocortin receptor agonist that acts on central nervous system pathways involved in sexual desire and arousal. Unlike PDE-5 inhibitors, it does not primarily act on vascular mechanisms but instead modulates neural signaling related to sexual response.
Potential Clinical Applications
Adjunctive option in patients not responding to traditional therapies
Sexual arousal support
(central mechanism)
Low libido and decreased sexual interest
Hypoactive sexual desire disorder (HSDD) in appropriate patients
Clinical Rationale
PT-141 is associated with activity in:
Modulation of dopamine and excitatory sexual response pathways
Central melanocortin receptor activation (MC3R, MC4R)
Enhancement of sexual desire and arousal signaling
This mechanism targets the neurobiologic components of sexual function rather than peripheral blood flow.
Administration
Typically administered via subcutaneous injection on an as-needed basis prior to anticipated sexual activity. Protocols are individualized based on patient response and goals.
Wellness & Sexual Health Focus
This therapy is positioned as a targeted, neurohormonal approach to improving sexual desire and addressing central contributors to sexual dysfunction, within a broader biopsychosocial care model.
This information is provided for educational purposes and reflects a general overview of studied biologic mechanisms. Statements have not been evaluated by the FDA. Individual protocols, appropriateness, and outcomes are determined on a case-by-case basis following clinical evaluation. Individual results may vary.